PDGF

Human medicines European public assessment report (EPAR): Kisplyx, lenvatinib, Date of authorisation: 25/08/2016, Revision: 21, Status: Authorised

Retrieved on: 
Friday, January 5, 2024
Marketing, Hypothyroidism, INN, Woman, Progression-free survival, Nausea, Syndrome, Heart, Cancer, Inflammation, Skull, Proteinuria, Anatomy, Cell division, IIA, Diarrhea, Fatigue, ATC, Capsule, Bleeding, Pancreas, RET, VEGF, FGFR, Cerebral edema, Neoplasm, Stroke, Enzyme, Liver failure, Safety, Kidney cancer, Arthralgia, Heart failure, Patient, Urine, Medical Subject Headings, Stomatitis, Immune system, Everolimus, International, Encephalopathy, Language, Somatic symptom disorder, Blood, Mouth, Catherine Disher, Select, Medicine, Vomiting, Pembrolizumab, Cholesterol, PDGF, Kidney failure, Weight loss, Headache, KIT, Brain, Acral lentiginous melanoma, Swelling, Hypoesthesia, Splenic infarction, Confusion, European Medicines Agency, RCC, Kidney, Growth, Sunitinib, Hypercholesterolemia, Rash, Medical device

Human medicines European public assessment report (EPAR): Kisplyx, lenvatinib, Date of authorisation: 25/08/2016, Revision: 21, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Kisplyx, lenvatinib, Date of authorisation: 25/08/2016, Revision: 21, Status: Authorised

RedDress Launches ActiGraft PRO with G-Code Reimbursement Status for the US Wound Care Market

Retrieved on: 
Tuesday, July 18, 2023
DFU, Insurance, Diabetes, PDGF, Thrombus, Human, Amputation, Foot, National coverage determination, Mouth ulcer, Platelet-rich plasma, NCD, Medicare, Plasma, TEL, PRP, Patient, Fibrin, Physician, Blood, FDA, Wound healing, Health insurance, Hospital

TEL AVIV, Israel and JACKSONVILLE, Fla., July 18, 2023 /PRNewswire/ -- RedDress, a personalized and autologous wound care solution created from patients own whole blood, today announced that its ActiGraft PRO product is now commercially available throughout the US and is eligible for reimbursement nationally from Medicare and Medicare Advantage via NCD 270.3 and G-0465 & G-0460 codes. ActiGraft PRO is the most advanced whole-blood wound care solution on the market, offering a quick procedure time while eliminating the need for a centrifuge or a needle for blood transfer. Reimbursement for the procedure through Medicare and Medicare Advantage is $1726 per application for up to 20 applications in hospital outpatient facilities and wound care centers.

Key Points: 
  • ActiGraft PRO is the most advanced whole-blood wound care solution on the market, offering a quick procedure time while eliminating the need for a centrifuge or a needle for blood transfer.
  • Reimbursement for the procedure through Medicare and Medicare Advantage is $1726 per application for up to 20 applications in hospital outpatient facilities and wound care centers.
  • "Launching ActiGraft PRO, our most advanced wound care product, along with Medicare reimbursement status for patients across the US, is a significant milestone for us as a company and for the national wound care market as a whole", said Alon Kushnir, CEO and co-founder of RedDress.
  • The ActiGraft PRO system is an autologous, point-of-care wound management solution created from patient's whole blood.

UPSIDE Foods Announces What's Next on the Menu: A Mouth-Watering Array of Ground Meat Products Made from Real Animal Cells

Retrieved on: 
Thursday, April 20, 2023
PDGF, Use of Free and Open-Source Software (FOSS) in the U.S. Department of Defense, Poultry, Eating, Vegetable, Cell, History, Upside Foods, U.S. Department of Agriculture Cotton Annex, USDA, Love, FDA, SVP, Meat, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Spice, Food, Poultry farming, Animal husbandry, Research

Pending regulatory review, these cultivated ground meat products will broaden UPSIDE's commercial portfolio to include a range of delicious options, such as chicken sausages, chicken sandwiches and dumplings.

Key Points: 
  • Pending regulatory review, these cultivated ground meat products will broaden UPSIDE's commercial portfolio to include a range of delicious options, such as chicken sausages, chicken sandwiches and dumplings.
  • This includes the development of both whole-textured products, such as chicken filets, and ground meat products with simpler textures that can be scaled up quickly and at a lower cost.
  • UPSIDE's ground meat products will be made up of real animal cells, along with other ingredients like herbs, vegetables, spices, and plant-based proteins.
  • Meanwhile, UPSIDE will continue working with both FDA and USDA to bring its next generation of products to market.

Wound Care Global Market Report 2023: Sector to Reach $29.57 Billion by 2030 at a 4.15% CAGR - ResearchAndMarkets.com

Retrieved on: 
Monday, April 17, 2023
Surgery, Health, Medical Devices, Platelet-derived growth factor, PDGF, Diabetes, Infection, Ageing, Foot, USD, Market, Regeneration, Protein, Patient, Education minister, Mode, Retail, Speciality chemicals, Pharmaceutical industry, Nursing, Silk, Application

The global wound care market size is anticipated to reach USD 29.57 billion by 2030, expanding at 4.15% CAGR from 2023 to 2030.

Key Points: 
  • The global wound care market size is anticipated to reach USD 29.57 billion by 2030, expanding at 4.15% CAGR from 2023 to 2030.
  • Similarly, 3D printing technology has revolutionized the production of custom-made wound care products, such as prosthetic limbs, orthotics, and wound dressings.
  • For instance, Human Biosciences planned on launching two new wound care products in the Indian market.
  • However, the retail sales segment is anticipated to witness the fastest growth, with a CAGR of 4.53% over the forecast period
    Chapter 3 Wound Care Market Variables, Trends & Scope
    Chapter 4 Wound Care Market: Segment Analysis, By Product, 2018 - 2030 (USD Million)
    Chapter 5 Wound Care Market: Segment Analysis, By Application, 2018 - 2030 (USD Million)
    Chapter 6 Wound Care Market: Segment Analysis, By End-use, 2018 - 2030 (USD Million)
    Chapter 7 Wound Care Market: Segment Analysis, By Mode Of Purchase, 2018 - 2030 (USD Million)
    Chapter 8 Wound Care Market: Segment Analysis, By Distribution Channel, 2018 - 2030 (USD Million)
    Chapter 9 Wound Care Market: Regional Market Analysis, By Product, By Application, By End-Use, By Mode Of Purchase, By Distribution Channel, 2018 - 2030 (USD Million)

Diabetic Foot Ulcer Treatment Global Market Report 2022: Success found in Various Adjuvant Therapies Fuels Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 13, 2022
Health, Diabetes, Chronic kidney disease, Diabetes, 66, Stroke, Diabetic foot ulcer, B cell, Wound healing, COVID-19, Biopharmaceutical, PICO, Kidney failure, CAGR, Patient, Mortality, Severe cognitive impairment, Infarction, Treatment, Hyperglycemia, GDP, DFU, Amputation, Platelet-derived growth factor, International Diabetes Federation, ConvaTec, PDGF, VEGF, USD, Niece and nephew, Pharmaceutical industry, Peripheral neuropathy

The "Diabetic Foot Ulcer Treatment Market Size, Share & Trends Analysis Report by Treatment (Biologics, Wound Care Dressings), by Ulcer Type (Neuro-ischemic, Ischemic, Neuropathic), by End-use, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Diabetic Foot Ulcer Treatment Market Size, Share & Trends Analysis Report by Treatment (Biologics, Wound Care Dressings), by Ulcer Type (Neuro-ischemic, Ischemic, Neuropathic), by End-use, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.
  • The global diabetic foot ulcer treatment market size is expected to reach USD 7.77 billion by 2030, registering a CAGR of 5.9% from 2022 to 2030, according to this report.
  • Many adjuvant therapies such as nonsurgical debridement agents, dressings and topical agents, oxygen therapies, negative pressure wound therapy, acellular bioproducts, human growth factors, energy-based therapies, and systemic therapies are said to effectively improve and cure DFU.
  • Biologics include growth factors [such as Vascular Endothelial Growth Factor (VEGF) and Platelet-Derived Growth Factor (PDGF)], stem cells, and other anti-diabetic drugs.

Gastrointestinal Stromal Tumors Drug Pipeline Market Report 2022: Comprehensive Insights About 25+ Companies and 28+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 11, 2022
Research, Packaging, Chemicals, Plastics, Clinical Trials, Manufacturing, Biotechnology, Pharmaceutical, Health, Science, Other Science, News, Disease, Therapy, DXD, NDA, Chronic myelogenous leukemia, Patient, Stromal cell, Cell proliferation, KIT, GIST, Technology, Cancer, III, Daiichi Sankyo, Nilotinib, Discovery, Acquisition, Jiangsu Hengrui Medicine, CML, Adult, Gastrointestinal stromal tumor, ADC, Clinical trial, PDGF, Medical imaging, Pharmaceutical industry, Fine chemical

The "Gastrointestinal Stromal Tumors - Pipeline Insight, 2022," report provides comprehensive insights about 25+ companies and 28+ pipeline drugs in Gastrointestinal Stromal Tumors pipeline landscape.

Key Points: 
  • The "Gastrointestinal Stromal Tumors - Pipeline Insight, 2022," report provides comprehensive insights about 25+ companies and 28+ pipeline drugs in Gastrointestinal Stromal Tumors pipeline landscape.
  • The assessment part of the report embraces, in depth Gastrointestinal Stromal Tumors commercial assessment and clinical assessment of the pipeline products under development.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Gastrointestinal Stromal Tumors R&D.
  • The companies which have their Gastrointestinal Stromal Tumors drug candidates in the most advanced stage, i.e.

Angion Announces Phase 1b Trial of ANG-3070 in Patients with Idiopathic Pulmonary Fibrosis

Retrieved on: 
Monday, May 16, 2022
Epithelium, DDR1, Fibroblast, Private Securities Litigation Reform Act, Food, Survival, U.S. Securities and Exchange Commission, Patient, NASDAQ, ROCK2, CYP11B2, Prescription, COVID-19, PDGF, Cell, Kidney, FDA, IND, DDR2, Plasma, Fibrosis, Safety, Pathology, Degenerative disease, Lung, Therapy, Security (finance), Idiopathic pulmonary fibrosis, IPF, PK, Arm, Investigational New Drug, GLOBE, Pharmaceutical industry, Vaccine

UNIONDALE, N.Y., May 16, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today announced U.S. Food and Drug Administration’s (FDA) acceptance of an Investigational New Drug (IND) application supporting the clinical development of ANG-3070 in idiopathic pulmonary fibrosis (IPF) and clearance to begin a Phase 1b study of ANG-3070 in patients with IPF.

Key Points: 
  • IPF patients eligible for this Phase 1b study of ANG-3070 include those who have discontinued nintedanib or pirfenidone, refused treatment with nintedanib or pirfenidone, or those who are treatment nave.
  • Approximately 20 IPF patients will be enrolled into a crossover design trial with four arms dosing for ten days each.
  • A Phase 1b trial of ANG-3070 in patients with idiopathic pulmonary fibrosis is targeted to enroll and report data in 2022.
  • A Phase 1b trial of ANG-3070 in patients with idiopathic pulmonary fibrosis is targeted to enroll and report data in 2022.

Galecto Completes Enrollment in Global Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of IPF

Retrieved on: 
Tuesday, April 26, 2022
Patient, Inhalation, Fibrosis, Idiopathic pulmonary fibrosis, U.S. Securities and Exchange Commission, Security (finance), Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NASDAQ, Food, Cirrhosis, Private Securities Litigation Reform Act, FVC, LOXL2, GLOBE, Ruxolitinib, Mortality, Vital capacity, NSCLC, Plasma, PDGF, Platelet-derived growth factor, SEC, Safety, IPF, HIV disease progression rates, Disease, FDA, Boehringer Ingelheim, Therapy, Cancer, Pharmaceutical industry, Galecto Biotech

BOSTON, April 26, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced it has completed enrollment of patients in its Phase 2b GALACTIC-1 trial of GB0139 for idiopathic pulmonary fibrosis (IPF).

Key Points: 
  • We are very excited to complete enrollment in this Phase 2b trial in IPF and are encouraged by the support of the clinical investigators and patients participating in the trial.
  • GALACTIC-1 is a randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 2b study being conducted across approximately 100 centers globally.
  • The study is designed to investigate the safety and efficacy of Galectos most advanced compound, GB0139, in 141 patients with IPF.
  • GB0139 for the treatment of IPF has been granted Orphan Drug Designation by both U.S. and European regulatory authorities.

CytoImmune Therapeutics Announces Publication Demonstrating Platelet-Derived Growth Factor D Signaling Activates Natural Killer (NK) Cells and Enhances NK Cell Survival

Retrieved on: 
Tuesday, January 25, 2022
City of Hope National Medical Center, PNAS, City of Hope, BCMA, Biology, GPRC5D, Acute myeloid leukemia, Gene, National academy, Research, Lung cancer, Tumor microenvironment, FLT3, Technology, CAR, Therapy, City, PSCA, National, Cancer, Patient, Engineering, PDGF, Large-cell lung carcinoma, Multiple myeloma, TOA, Survival, Neoplasm, GLOBE, Patent, Pharmaceutical industry, Mobile phone, Vaccine, Hope, Caligiuri, NK

City of Hope licensed several patent applications to CytoImmune to develop a portfolio of chimeric antigen receptor (CAR) NK cell therapies.

Key Points: 
  • City of Hope licensed several patent applications to CytoImmune to develop a portfolio of chimeric antigen receptor (CAR) NK cell therapies.
  • "We are excited to share this data on the role of PDGF-D-PDGFR signaling in NK cells' survival.
  • This foundational data supports CytoImmune's engineering approach to enhance NK cells' survival by introducing secretory IL-15 into each NK cell.
  • This collective knowledge and experience is utilized to engineer NK cells by focusing on the tumor-reactive NK cell subset.

Global PDGFR Inhibitors Market (2021 to 2026) - Featuring AstraZeneca, Bayer and Eli Lilly Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, October 22, 2021
Pharmaceutical, Health, Oncology, Safety, Cancer, Data, Partnership, Patient, FDA, PDGF, Drinking, Mastocytosis, Time, PDGFR, Smoking, Growth, Awareness, Prevalence, GIST, Tumor microenvironment, Pharmaceutical industry

Avapritinib sold under brand name Ayvakit is the first approved PDGFR inhibitor available in market.

Key Points: 
  • Avapritinib sold under brand name Ayvakit is the first approved PDGFR inhibitor available in market.
  • The drug was developed by Blueprint Medicines and is mainly indicated for the treatment of gastrointestinal tumors (GIST) and mastocytosis.
  • Although the market is poised to growth in coming years but several factors limits their growth in market.
  • This will increase the demand of targeted therapies, thus driving the growth of PDGFR inhibitor market.